An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-501522-38-00

Acronym

M19-388

Enrollment

Registered

2023-03-07

Start date

2020-09-04

Completion date

Unknown

Last updated

2025-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Lymphocytic Leukemia, Chronic lymphocytic leukemia; Non-Hodgkin's lymphoma; Multiple Myeloma; Acute Myeloid Leukemia

Brief summary

Adverse event collection

Interventions

DRUGVenetoclax

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Adverse event collection	—

Countries

Belgium, Denmark, France, Greece, Ireland, Poland, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026